Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Priority Review Vouchers One Step Closer, But Congress Must Act Again

Executive Summary

FDA will not be able to review applications covered by a priority review voucher until it receives Congressional authorization to collect a special user fee to support the program, the agency says in a draft guidance on the new incentive for pharmaceutical companies

Related Content

Patent Office Mulls Voucher For Fast-Track Re-exam If Firms Create "Humanitarian" Technology
Pfizer, Merck And Sanofi Show Interest In Priority Review Voucher Program
FDA Mulls “Fast Track” Approach For Priority Review Voucher Eligibility
Priority Review Vouchers: Coartem And The Importance Of Perceptions
Should FDA prioritize more tropical disease drugs?
FDA Priority Review Voucher Guidance Coming: Incentive Has Low Visibility
Novartis Malaria Combo Set For FDA Committee Review
Novartis Coartem Malaria NDA May Be First For Priority Review Voucher
Biotech Sector Considers New Funding Vehicle: FDA Priority Review Voucher
Direct To Consumer User Fee Program Formally Ends



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts